Search Results
Your search for ,wAs matches 27466 pages
Showing 10051 - 10100FDA Approves Companion Diagnostic for Three Targeted Therapies for Advanced Ovarian, Breast, and Non–Small Cell Lung Cancers
On October 27, the U.S. Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx test for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies. The new indications are for alpelisib (Piqray) in ...
Trends and Outcomes Among Hispanic Women of Different Races With Breast Cancer
In a National Cancer Database analysis reported in JCO Oncology Practice, Champion et al identified patterns in disease characteristics, time to surgery, and overall survival among Hispanic patients of different races and among Hispanic and non-Hispanic women of the same race. Study Details The...
Stereotactic Radiosurgery May Delay Cognitive Deterioration vs WBRT in Patients With Numerous Brain Metastases
Stereotactic radiosurgery (SRS) may represent a new standard of care for patients with four or more brain metastases, replacing whole-brain radiation therapy (WBRT) in this setting, according to a phase III study presented at the virtual 2020 American Society for Radiation Oncology (ASTRO) Annual...
Fluciclovine PET Imaging vs Conventional Imaging in Prostate Cancer
The addition of the radiotracer fluciclovine to positron-emission tomography (PET) imaging for treatment planning led to superior failure-free survival compared with conventional imaging in men with prostate cancer who had undergone radical prostatectomy and were experiencing biologic recurrence of ...
Targeted Inhibitor of Mutant KRAS Gene Shows Activity in Early Trial
Adagrasib (MRTX849), a novel agent that targets a mutated form of the KRAS gene—the most commonly altered oncogene in human cancers, and one long considered “undruggable”—caused tumor shrinkage in most patients in a clinical trial, with manageable side effects, researchers reported at the 32nd...
Companion Diagnostic to Identify NTRK Fusions in Patients With Solid Tumors Eligible for Treatment With Larotrectinib Approved by the FDA
On October 23, the U.S. Food and Drug Administration (FDA) approved the next-generation sequencing–based FoundationOne CDx test as a companion diagnostic to identify fusions in the neurotrophic receptor tyrosine kinase (NTRK) genes NTRK1, NTRK2, and NTRK3 in DNA isolated from tumor tissue specimens ...
Survey Shows Many Patients With Cancer Willing to Take Part in Clinical Trials Despite Coronavirus
Patient Power, a patient-driven cancer news organization, reported that a majority of patients with cancer still want to participate in clinical trials despite the COVID-19 pandemic, according to a recent survey of 1,485 patients. The Patient Power COVID-19 Cancer Trial Survey, the second Patient...
SHP2 Inhibition May Counter Resistance Mechanisms in Lung Cancer
Recent preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, an affiliate of Navire Pharma, found that the novel SHP2 inhibitor IACS-13909 may be able to overcome therapeutic resistance mechanisms in non–small cell lung cancer (NSCLC). The data, which...
Becoming Acquainted With Cancer
Editor’s Note: The ASCO Post learned of the death of Patrick Beauregard due to colorectal cancer on September 6, 2020. Just weeks after my wedding in late summer of 2017, I had a sudden bout of abdominal pain so severe that it sent me to the emergency room. I was just 29 years old and in great...
Remembering Patrick H. Beauregard: ‘Selfless in His Efforts to Raise Awareness’ of Colorectal Cancer in Young Adults
The editors of The ASCO Post are sad to report the death of Patrick H. Beauregard on September 6, 2020. The cause was colorectal cancer. Diagnosed with stage IV disease in 2017 at the age of 29, Mr. Beauregard dedicated the last 3 years of his life to raising awareness of colorectal cancer in...
Early-Career ASCO Member and Breast Medical Oncologist, Tomas Lyons, MB BCh, BAO, MRCPI, Dies at 38
Tomas Lyons, MB BCh, BAO, MRCPI, a medical oncologist at the Evelyn H. Lauder Breast Center Memorial Sloan Kettering Cancer Center in New York, died suddenly on September 29 at the age of 38. During his career at Memorial Sloan Kettering (MSK), he was a celebrated collaborator on multidisciplinary ...
Joan H. Marks, Pioneer in Genetic Counseling, Dies at 91
Joan H. (Rosen) Marks, a pioneer in genetic counseling, died on September 14, 2020. She was 91. Ms. Marks received an honorary Doctor of Science degree from Sarah Lawrence College in Bronxville, New York, in 2019, in recognition of her contributions and leadership to the College and to society, the ...
Continued Benefit of First-Line Nivolumab vs Dacarbazine in Advanced BRAF Wild-Type Melanoma
The 5-year outcomes of the CheckMate 066 trial, reported in the Journal of Clinical Oncology by Caroline Robert, MD, PhD, of Gustave Roussy, Villejuif, France,and colleagues, show continued benefit of first-line nivolumab vs dacarbazine in advanced BRAF wild-type melanoma and support evidence that ...
Your Stories: ‘The Family Business’
International business leader Riccardo Braglia has experienced great losses due to cancer. In “The Family Business,” he shares with ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO, how the perspective he gained inspires what he gives to help patients everywhere. “My grandmother, my ...
Expect Questions About Increased Cancer Mortality Risk Among Patients Diagnosed With DCIS
A large cohort study1 finding that the risk of dying of breast cancer was increased threefold after a DCIS diagnosis may cause patients diagnosed with DCIS to ask what they can do to reduce that risk. Currently, there is little that most patients can do. “The lifetime risk of death following DCIS...
Focus on Preventing Invasive Recurrence in Women With DCIS Does Not Sufficiently Address Breast Cancer Mortality
A study published recently by Giannakeas et al looked at the risk of death from breast cancer for women diagnosed with ductal carcinoma in situ (DCIS).1 The investigators anticipated that treatment would eliminate the risk of invasive ipsilateral recurrence and prevent subsequent mortality from...
Emily Whitehead, Early Recipient of CAR T-Cell Therapy for ALL, Celebrates 8 Years Cancer-Free
Among the success stories in the treatment of acute lymphoblastic leukemia (ALL) in children and young adults is the development of chimeric antigen receptor (CAR) T-cell therapy. The field of cellular immunotherapy was still in its infancy in 2012 when Emily Whitehead, then 7, became the first...
Personal Testimonial: CAR-modified T Cells in Adults
Twelve adults with chronic lymphocytic leukemia (CLL) have been treated with CD19-targeted chimeric antigen receptor (CAR) T-cell therapy at the University of Pennsylvania in Philadelphia by Carl June, MD, Richard W. Vague Professor in Immunotherapy, and colleagues. These were all end-stage...
Preliminary Progress with Genetically Engineered T Cells in Treating Childhood ALL
Two small phase I studies at separate centers demonstrated encouraging results in the treatment of children with acute lymphoblastic leukemia (ALL) using reinfused autologous genetically engineered T cells. Results of both studies were presented at the Annual Meeting of the American Association for ...
New ASCO-SEP Edition Available: Expands Reach to Global Oncology Community
The seventh edition of the ASCO Self-Evaluation Program® (ASCO-SEP®) is now available online, expanding its reach to physicians and advanced practitioners. The latest edition features new content that addresses oncologic care in a global setting. The new edition of ASCO-SEP includes 22 chapters of...
Bloodletting by a Phleam
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. Photograph courtesy of Stanley B. Burns, MD, and The Burns Archive. For ...
UICC Welcomes New President, President-Elect, and Board of Directors for 2020–2022
At the recent General Assembly of the Union for International Cancer Control (UICC), which was held virtually for the first time, Anil D’Cruz, MD, of India, was welcomed as the organization’s new President. Full member organizations also elected the 2020–2022 Board of Directors, including...
Recurrence-Free Survival Benefit Maintained With Adjuvant Nivolumab vs Ipilimumab in Stage IIIB–IIIC and IV Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, and colleagues, 4-year results of the CheckMate 238 trial show continued benefit of adjuvant nivolumab vs ipilimumab in recurrence-free survival and metastasis-free...
Breast Cancer and Radiation Researcher David Gius, MD, PhD, Joins Mays Cancer Center
David Gius, MD, PhD, a breast cancer and radiation researcher, has joined the Mays Cancer Center, home to The University of Texas Health San Antonio MD Anderson. He was recruited to the Mays Cancer Center from the Robert H. Lurie Comprehensive Cancer Center at Northwestern University with a $6...
The Secret History of Cancer Chemotherapy
“The summons came in the middle of the night. He was awake at the first harsh jangle of the telephone…. Always a light sleeper, Lieutenant Colonel Stewart Francis Alexander attributed the trait to his father, an old-fashioned family practitioner whose response to every late-night distress call was...
A Gritty Journey Into a Rare Cancer and Back
Over the past decade, a prolific number of cancer memoirs have been published, and some have been award-winning bestsellers. When entering a crowded genre, it is best to have something that sets your story apart. Judith Dwyer Fugate did just that with a memoir about a rare tumor that has rarely if...
Cleveland Clinic Announces Oncology Staff Appointments
Cleveland Clinic recently announced the following additions to its oncology staff: Ruth Keri, PhD, has joined Cleveland Clinic Lerner Research Institute Department of Cancer Biology. She will study breast cancer, focusing on identifying the molecular processes that control the formation of breast...
UCLA Researchers’ Efforts in Melanoma Receive $13M Boost From NIH
University of California, Los Angeles (UCLA) researchers have received a $13 million grant from the National Institutes of Health (NIH) to find new ways to overcome melanoma resistance to some of the most promising targeted therapies and immunotherapies. There have been significant advancements in...
The Gut, Our Choices, and Gynecologic Cancers: Investigating an Unlikely Trio
Disturbance of the gut microbial metabolism is thought to be the root cause of human diseases. Bacteria, viruses, and fungi affect their human hosts in numerous ways. There is evidence to support the theory that microbes, through their genetic makeup, gene products, and metabolites, play a role in...
Expert Point of View: Bartosz Chmielowski, MD, PhD
The invited discussant of LEAP-004, Bartosz Chmielowski, MD, PhD, Associate Clinical Professor at the University of California Los Angeles Jonsson Comprehensive Cancer Center, commented: “The response rate of 21% was quite impressive for this patient population. Patients previously treated with an...
Advanced Melanoma: Lenvatinib Plus Pembrolizumab After Disease Progression on Anti–PD-1 Therapy
Checkpoint inhibitors can be lifesaving for many patients with advanced melanoma, but those who experience disease progression currently have few treatment options. The combination of a tyrosine kinase inhibitor and an anti–PD-1 agent may offer some hope in this setting, according to a study of...
Pay-for-Performance Program to Reimburse Oncology Practices for Prescribing Evidence-Based Cancer Drugs
A pay-for-performance program that offers enhanced reimbursement to oncology practices for prescribing high-quality, evidence-based cancer drugs increased use of these drugs without significantly changing total spending on care, Penn Medicine researchers reported in a study published in the Journal ...
Expert Point of View: Salah-Eddin Al-Batran, MD
Salah-Eddin Al-Batran, MD, Director of the Institute of Clinical Cancer Research and Director of GI Oncology at Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, commented on KEYNOTE-590 at a press briefing. Dr. Al-Batran noted that the prognosis for advanced esophageal cancer is...
First-Line Pembrolizumab Plus Chemotherapy Improves Survival in Esophageal Cancer
As first-line therapy for advanced esophageal cancer, pembrolizumab added to chemotherapy improved overall survival in the KEYNOTE-590 population. Not only did patients with high PD-L1 expression benefit, the value of checkpoint inhibition was observed for the whole population, the trial’s...
Panel With Diverse Perspectives Explores Strategies to Reduce Costs for Cancer Care
“Imagine that it’s 5 years from now, and we are in a situation where the cost of cancer care has flattened, and costs are even going down,” said Clifford Goodman, PhD, a Senior Vice President at the Lewin Group, turning to a panel of oncology and policy experts at his side. “What policies got us...
Isabelle Tabah-Fisch, MD, Drug Researcher, Industry Executive, Dies at 64
Isabelle Tabah-Fisch, MD, a medical oncologist in Paris who contributed greatly to drug development, died August 28, 2020, at age 64. An announcement about Dr. Tabah-Fisch’s death was made by GamaMabs, where she served as Chief Medical Officer until her retirement in March 2020. Under her...
Lesley Solomon, MBA, of Dana-Farber, Receives Extraordinary Women Advancing Healthcare Award
Lesley Solomon, MBA, Senior Vice President for Innovation and Chief Innovation Officer at Dana-Farber Cancer Institute, has received the 2020 Extraordinary Women Advancing Healthcare Award from The Commonwealth Institute, a nonprofit organization devoted to advancing women in leadership positions....
Daughter of an Orthopedic Surgeon, Abigail T. Berman, MD, Finds Radiation Oncology Intriguing
Radiation oncologist Abigail T. Berman, MD, was born and reared in Philadelphia, the daughter of an orthopedic surgeon whose passion for his work was an early influence on her decision to pursue a career in medicine. “My father absolutely adored his job and worked very hard, which inspired me to...
Surgical and Radiation Oncology in Elderly Patients With Cancer
As one might expect, the focus on older patients developed in surgical and radiation oncology at the same time as in medical oncology. As we have done in our overview of medical oncology, we may recognize a prehistory, past history, and present history in surgical and radiation geriatric oncology....
Cancer in Older Adults: The History of Geriatric Oncology, Part 2: 1990–2020
In part 1 of this three-part article, which was published in the October 10, 2020, issue of The ASCO Post, we chronicled the progress made in geriatric oncology up to the decade of the 1990s, which saw an explosion of research activity in the study of aging and cancer. In part 2, we review the...
James K. McCloskey II, MD, Named Division Chief of the Division of Leukemia at John Theurer Cancer Center
James K. McCloskey II, MD, was named Division Chief of the Division of Leukemia at Hackensack Meridian John Theurer Cancer Center (JTCC), part of Hackensack University Medical Center. Dr. McCloskey previously served as Interim Chief for the Division of Leukemia and will continue in his role as...
Expert Point of View: Chiara Cremolini, MD, PhD
The KEYNOTE-177 invited discussant, Chiara Cremolini, MD, PhD, of the University of Pisa, Italy, welcomed the patient-reported outcomes of the study, noting that such data are frequently missing. “Unfortunately, quality of life is an often-disregarded issue in colorectal cancer clinical trials,”...
First-Line Pembrolizumab in Metastatic Colorectal Cancer: Quality of Life Also Improved
In KEYNOTE-177, the anti–PD-L1 antibody pembrolizumab reduced the risk of disease progression by 40% vs chemotherapy in a targeted subset of previously untreated patients with metastatic colorectal cancer. Now, in terms of health-related quality of life, pembrolizumab is also the clear favorite,...
Activity of the KRAS G12C Inhibitor Sotorasib in KRAS G12C–Mutant Advanced Solid Tumors
As reported inThe New England Journal of Medicine by David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, a phase I trial (CodeBreak 100) has shown activity of the oral KRAS G12C inhibitor sotorasib in heavily pretreated patients with KRAS G12C–mutant...
Capmatinib Active in Advanced NSCLC With MET Exon 14 Skipping Mutations
As reported inThe New England Journal of Medicine by Jürgen Wolf, MD, of the Center for Integrated Oncology, University Hospital Cologne and University of Cologne, and colleagues, the phase II GEOMETRY mono-1 trial has shown durable responses with the selective MET inhibitor capmatinib in patients...
Thinking Out of the Box to Advance the Management of Chronic Graft-vs-Host Disease
Over the past decade, the field of allogeneic hematopoietic cell transplantation has made great strides, evolving into a curative procedure for blood cancers that once were almost always fatal. However, chronic graft-vs-host disease, whose biologic etiology remains unclear, continues to be the...
Expert Point of View: Henrik Grönberg, MD
Formal discussant of the -IPATential150 trial, Henrik Grönberg, MD, Professor at Karolinska Institute, Stockholm, found the study results intriguing, especially in the PTEN-loss patients. “Biomarkers are the wave of the future,” he said. “The study population was compared with an adequately...
Ipatasertib/Abiraterone Combination Shows Potential in Metastatic Castration-Resistant Prostate Cancer With PTEN Loss
Ipatasertib plus abiraterone plus prednisone achieved significantly superior radiographic progression–free survival and antitumor activity compared with placebo plus abiraterone plus prednisonein patients with metastatic castration-resistant prostate cancer and PTEN loss, according to the results...
Florida Surgeon Steven D. Wexner, MD, FACS, Elected Vice-Chair of Board of Regents of American College of Surgeons
Steven D. Wexner, MD, PhD (Hon), FACS, FRCS (Eng), FRCS (Ed), FRCSI (Hon), Hon FRCS (Glasg), was recently elected Vice-Chair of the Board of Regents of the American College of Surgeons (ACS) during the College’s virtual Clinical Congress 2020, held October 3–7. Dr. Wexner is Chair of the...
Expert Point of View: Henrik Grönberg, MD
Formal discussant of the PROfound trial, Henrik Grönberg, MD, of the Karolinska Institute, Stockholm, agreed that this was a practice-changing trial for select patients. “The patient population is representative, but the problem is the control group, which included patients who experienced disease ...
